Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis. Issue 12 (December 2022)

• Record Type: Journal Article
• Authors: Albuquerque, Thaís Rodrigues de; Macedo, Luis Fernando Reis; Delmondes, Gyllyandeson de Araújo; Rolim Neto, Modesto Leite; Almeida, Thales Marcon; Uchida, Ricardo Riyoiti; Cordeiro, Quirino; Lisboa, Kenya Waléria de Siqueira Coelho; Menezes, Irwin Rose Alencar de
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 42:Issue 12(2022)
• Page Start: 2175
• Page End: 2187
• Publication Date: 2022-12
• Subjects: Meta-analysis -- mental disorders -- post-traumatic stress disorder (PTSD) -- stress disorders -- ketamine; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X221116477
• Languages: English
• ISSNs: 0271-678X

Abstract

Post-traumatic stress disorder (PTSD) is an anxiety disorder with manifestations somatic resulting from reliving the trauma. The therapy for the treatment of PTSD has limitations, between reduced efficacy and "PTSD pharmacotherapeutic crisis". Scientific evidence has shown that the use of ketamine has benefits for the treatment of depressive disorders and other symptoms present in PTSD compared to other conventional therapies. Therefore, this study aims to analyze the available evidence on the effect of ketamine in the treatment of post-traumatic stress. The systematic review and the meta-analysis were conducted following PRISMA guidelines and RevManager software, using randomized controlled trials and eligible studies of quality criteria for data extraction and analysis. The sample design evaluated included the last ten years, whose search resulted in 594 articles. After applying the exclusion criteria, 35 articles were selected, of which 14 articles were part of the sample, however, only six articles were selected the meta-analysis. The results showed that the ketamine is a promising drug in the management of PTSD with effect more evident performed after 24 h evaluated by MADRS scale. However, the main limitations of the present review demonstrate that more high-quality studies are needed to investigate the influence of therapy, safety, and efficacy.